Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa

APMIS

Volumn 123, Issue 2, 2015, Pages 175-183

  Farjah, Ali ^a,b   Owlia, Parviz ^a   Siadat, Seyed Davar ^b   Mousavi, Seyed Fazlollah ^b   Ardestani, Mehdi Shafiee ^c   Mohammadpour, Hashem Khorsand ^d  

^a SHAHED UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Iranian Blood Research and Fractionation Company   (Iran)

Author keywords

Alginate; Conjugate vaccine; Pseudomonas aeruginosa

Indexed keywords

ALGINIC ACID; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; PSEUDOMONAS VACCINE; BACTERIUM ANTIBODY; GLUCURONIC ACID; HEXURONIC ACID; IMMUNOGLOBULIN G; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; MEMBRANE VESICLE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE VESICLE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL LOAD; BAGG ALBINO MOUSE; BLOOD; CELL MEMBRANE; CYSTIC FIBROSIS; DRUG EFFECTS; IMMUNOLOGY; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VACCINATION;

ALGINATES; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; CELL MEMBRANE; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GLUCURONIC ACID; HEXURONIC ACIDS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; VACCINATION; VACCINES, CONJUGATE;

EID: 84921545718     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12337     Document Type: Article

References (45)

1. Wiens JR, Vasil AI, Schurr MJ, Vasil ML. Iron-regulated expression of alginate production, mucoid phenotype, and biofilm formation by Pseudomonas aeruginosa. MBio 2014;5: e01010-13.
2. Mousavi Nadoshan S, Owlia P, Moein Najafabadi L, Rasooli I, Saderi H, Salari MH. Effects of sub-inhibitory concentrations of essential oils of mentha spicata and cumminum cyminum on virulence factors of Pseudomonas aeruginosa. J Med Plants 2010;9(Suppl 6):124-130.
3. Salimi H, Yakhchali B, Owlia P, Lari AR. Molecular epidemiology and drug susceptibility of Pseudomonas aeruginosa strains isolated from burn patients. Lab Med 2010;41:123-345.
4. Hoiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001;3:23-35.
5. Pritt B, O'Brien L, Wnn W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol 2007;128:32-4.
6. Skjak-Braek G, Grasdalen H, Larsen B. Monomer sequence and acetylation pattern in some bacterial alginates. Carbohydr Res 1986;154:239-50.
7. Mai GT, Seow WK, Pier GB, McCormack JG, Thong YH. Suppression of lymphocyte and neutrophil functions by Pseudomonas aeruginosa mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments. Infect Immun 1993;61:559-64.
8. Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992;47:6-13.
9. Pier GB, Small GJ, Warren HB. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 1990;249:537-40.
10. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-8.
11. Branny P, Pearson JP, Pesci EC, Kohler T, Iglewski BH, Van Delden C. Inhibition of quorum sensing by a Pseudomonas aeruginosa dksA homologue. J Bacteriol 2001;183:1531-9.
12. Mathee K, Ciofu O, Sternberg C, Lindum PW, Campbell JI, Jensen P, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999;145(Pt 6):1349-57.
13. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-25.
14. Pier GB, DesJardin D, Grout M, Garner C, Bennett SE, Pekoe G, et al. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect Immun 1994;62:3972-9.
15. Pier GB, Matthews WJ Jr, Eardley DD. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J Infect Dis 1983;147:494-503.
16. Doring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008;26:1011-24.
17. Garner CV, DesJardins D, Pier GB. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide. Infect Immun 1990;58:1835-42.
18. Makela PH. Conjugate vaccines-a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health 2003;34:249-53.
19. Lindberg AA. Glycoprotein conjugate vaccines. Vaccine 1999;17(Suppl 2):S28-36.
20. Cryz SJ Jr, Furer E, Que JU. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect Immun 1991;59:45-50.
21. Kashef N, Behzadian-Nejad Q, Najar-Peerayeh S, Mousavi-Hosseini K, Moazzeni M, Djavid GE. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. J Med Microbiol 2006;55(Pt 10):1441-6.
22. Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun 2003;71:3875-84.
23. Campodonico VL, Llosa NJ, Bentancor LV, Maira-Litran T, Pier GB. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect Immun 2011;79:3455-64.
24. Donnelly JJ, Deck RR, Liu MA. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Immunol 1990;145:3071-9.
25. Granoff DM, Holmes SJ. Comparative immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines. Vaccine 1991;9(Suppl 1):S30-4.
26. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009;27(Suppl 2):B3-12.
27. Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol 2010;64:163-84.
28. Park SB, Jang HB, Nho SW, Cha IS, Hikima J, Ohtani M, et al. Outer membrane vesicles as a candidate vaccine against edwardsiellosis. PLoS ONE 2011;6:e17629.
29. Danzig L. Meningococcal vaccines. Pediatr Infect Dis J 2004;23(Suppl 12):S285-92.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
31. Knutson CA, Jeanes A. A new modification of the carbazole analysis: application to heteropolysaccharides. Anal Biochem 1968;24:470-81.
32. Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, Robert J, et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996;14:1001-8.
33. Siadat SD, Norouzian D, Tabaraie B, Ahmadi H, Behzadiyannejad Q, Pirayeeh SN, et al. Comparative studies of conjugated capsular polysaccharide of neisseria meningitidis serogroup A with outer membrane vesicle of Neisseria meningitidis serogroup B. Res J Microbiol 2007;2:337-45.
34. Faezi S, Safarloo M, Amirmozafari N, Nikokar I, Siadat SD, Holder IA, et al. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection. APMIS 2014;122:115-27.
35. Ames P, DesJardins D, Pier GB. Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide. Infect Immun 1985;49:281-5.
36. Anderson TR, Montie TC. Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum. Infect Immun 1987;55:3204-6.
37. Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, et al. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine 2006;24:6240-9.
38. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-74.
39. Bryan LE, Kureishi A, Rabin HR. Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay. J Clin Microbiol 1983;18:276-82.
40. Pedersen SS, Espersen F, Hoiby N, Shand GH. Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 1989;27:691-9.
41. Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 2011;29:4881-90.
42. Haneberg B, Dalseg R, Oftung F, Wedege E, Hoiby EA, Haugen IL, et al. Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant. Dev Biol Stand 1998;92:127-33.
43. Siadat SD, Behzadiyannejad Q, Tabaraie B, Ahmadi H, Norouzian D, Pirayeeh SN, et al. Evaluation of serum bactericidal activity specific for Neisseria meningitidis Serogroup A and B: effect of immunization with Neisseria meningitidis Serogroup A Polysaccharide and Serogroup B Outer membrane vesicle conjugate as a bivalent meningococcus vac. Res J Microbiol 2007;2:436-44.
44. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004;82:488-96.
45. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993;11:293-306.